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Improvements over time in short-term mortality
following myocardial infarction in
HIV-positive individuals
Camilla Ingrid Hatleberga, Lene Ryoma, Wafaa El-Sadrb,
Colette Smithc, Rainer Weberd, Peter Reisse, Eric Fontasf,
Francois Dabisg, Matthew Lawh, Antonella d’Arminio Monfortei,
Stephane De Witj, Amanda Mocroftc, Andrew Phillipsc,
Jens D. Lundgrena, Caroline Sabinc, for the D:A:D Study Group
Objective: Few studies have described mortality and clinical outcomes after myo-
cardial infarction (MI) in the HIV-positive population. This study evaluated changes in
short-term mortality after MI in HIV-positive individuals in the D:A:D Study, and
investigated possible reasons for any changes seen.
Design: Prospective cohort study.
Methods: Demographic, cardiovascular disease (CVD)/HIV-related characteristics and
CVD-related interventions (invasive cardiovascular procedures and drug interventions)
were summarized at the time of and following anMI. Associations between calendar year
and mortality in the first month after MI were identified using logistic regression with
adjustment for confounders, including interventions received in the first month after MI.
Results: One thousand and eight HIV-positive individuals experiencing an MI over the
period 1999–2014 were included. The absolute number of MIs decreased from 214
(1999–2002) to 154 (2011–2014).Whilst the CVD risk profile remained high over time,
the HIV status improved. The use of CVD-related interventions after MI appeared to
increase over time. The proportion of individuals who died in the first month after MI
dropped from 26.6% in 1999–2002 to 8.4% in 2011–2014. Later calendar year was
associatedwith decreased short-termmortality; this effect was attenuated after adjusting
for CVD-related interventions received in the first month after MI [odds ratio changed
from 0.88 (95% confidence interval 0.83, 0.93) to 0.97 (0.91, 1.02)].
Conclusion: Improvements in short-term survival after MI appear to be largely driven
by improved medical management of CVD risk in HIV-positive individuals after MI.
Efforts are still needed to treat CVD risk factors and increase access to CVD-related
interventions. Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
AIDS 2016, 30:1583–1596
Keywords: cardiovascular disease, cardiovascular interventions, HIV infection,
mortality, myocardial infarction
aCHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
bICAP-Columbia University and Harlem Hospital, New York, USA, cResearch Department of Infection and Population Health,
UCL, London, UK, dDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich,
Zurich, Switzerland, eAcademic Medical Center, Department of Global Health and Division of Infectious Diseases, University of
Amsterdam, and HIV Monitoring Foundation, Amsterdam, The Netherlands, fDepartment of Public Health, Nice University
Hospital, Nice, gUniversite´ de Bordeaux, ISPED, Centre INSERM U897-Epide´miologie-Biostatistique, Bordeaux, France, hThe
Kirby Institute, UNSW Australia, Sydney, Australia, iDipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali,
Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy, and jDivision of Infectious Diseases, Saint Pierre University
Hospital, Universite´ Libre de Bruxelles, Brussels, Belgium.
Correspondence to Camilla Ingrid Hatleberg, MD, CHIP, Department of Infectious Diseases, Section 2100, Rigshospitalet,
University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Tel: + 45 35 45 57 70; fax: +45 35 45 57 57; e-mail: Camilla.hatleberg@regionh.dk
Received: 6 January 2016; revised: 17 February 2016; accepted: 18 February 2016.
DOI:10.1097/QAD.0000000000001076
ISSN 0269-9370 Copyright Q 2016 Wolters Kluwer Health, Inc. All rights reserved. 1583
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
The mortality rate after a first myocardial infarction (MI)
has declined in individuals of all ages in the general
population over the past 25 years [1,2]. This improvement
is mainly attributable to better management of cardio-
vascular disease (CVD) risk factors and the increased use
of recommended medical therapies and invasive cardi-
ovascular procedures (ICPs) [1,2]. It is well documented
that HIV-positive persons have a higher risk of CVD;
multiple factors, not all of which are fully explained, may
contribute to development of atherosclerosis in this
population. The prevalence of many traditional CVD risk
factors (e.g. smoking, dyslipidemia) is higher in HIV-
positive persons than in the general population [3,4].
Although some studies have reported an improvement
over the years [5], earlier findings from the D:A:D Study
demonstrated that the CVD risk profile of individuals
living with human immunodeficiency virus (HIV) in the
cohort generally worsened from 1999 to 2006 [6]. In
addition, exposure to some antiretroviral drugs has been
shown to be associated with an increased risk of MI
[7,8,9,10,11,12]. Furthermore, the increased CVD risk
noted in HIV-positive individuals may also be related to
HIV-related chronic inflammation and immunosuppres-
sion [10,8,13,14,15,16]. Whilst incidence rates of MI in
the HIV-positive population are higher than in the HIV-
negative population [17,18,13], there has been a decrease
in the rate over time in the D:A:D Study, likely as a result
of a more aggressive targeted approach to the manage-
ment of CVD risk factors [6]. Recent studies have also
reported a decreasing trend to the excess MI risk in HIV-
positive people compared with the general population in
later years [19,20].
Examples of independent predictors of increased
mortality after MI in the general population include
older age, male sex, in-hospital cardiac complications and
no ICP after MIs [21]. Previous findings have shown that
HIV-positive individuals admitted for acute coronary
syndromes faced a substantial short-term risk of death and
an increased risk of coronary revascularization, recurrent
MI [22] and all-cause mortality one year after MI [23].
However, few studies have described mortality and
clinical outcomes afterMI in the HIV-positive population
and changes in such outcomes over time. The primary
objective of this study was to investigate changes over
time in short-term mortality after MI in HIV-positive
participants in the D:A:D Study, and possible explanations
for any changes seen.
Material and methods
The D:A:D (Data on Adverse events of antiretroviral
Drugs) Study is a large, prospective observational cohort
study which follows >49 000 HIV-positive persons from
11 collaborating cohorts in Europe, USA and Australia; to
date, these persons have contributed >350 000 person-
years of follow-up (PYRS). The primary aim is to
investigate associations between the use of antiretroviral
drugs and risk of CVD [7]. The data include information
on socio-demographic factors, acquired immunodefi-
ciency syndrome (AIDS) events, CD4þ cell count, HIV
viral load, other laboratory results, antiretroviral-
regimen/treatment history and CVD risk factors/treat-
ments. Data are reported to the D:A:D coordinating
centre as anonymous, computerized case report files and
then merged into a standardized central dataset. All cases
of MI are validated centrally using criteria from the
WHO MONICA Study [24] and classified using a
Dundee score [24] as definite, possible or unclassifiable
and further distinguished into nonfatal and fatal events. In
addition, ICPs [coronary artery bypass graft (CABG),
carotid angioplasty (ANG) and carotid endarterectomy
(END)] are reported. Information on causes of death is
collected using a designated Coding of Causes of Death in
HIV (CoDe) form (www.chip.dk/code) [25]. This
analysis was conducted in accordance with the Declara-
tion of Helsinki and approved by national ethical
committee where necessary.
Statistical methods
All individuals experiencing an MI during prospective
follow-up from study initiation in 1999 to February 1,
2014, were identified. Demographic, HIV/CVD-related
characteristics and the use of CVD interventions [ICPs,
receipt of antiplatelets, angiotensin-converting enzyme
inhibitors (ACEIs), other antihypertensives (including
beta-blockers) and lipid-lowering drugs (LLDs)] were
described at the time of the MI and over the follow-up
period. Mortality after MI was described using Kaplan–
Meier methods, with follow-up on individuals who
remained alive being right-censored 6 months after their
last clinic visit or on 1st February 2014, whichever was
earlier. Only the first MI that occurred over follow-up
was considered for each individual (although some
individuals had experienced their first ever MI prior to
enrolment in the study).
Factors associated with overall mortality and mortality
from the first month after MI onwards were identified
using Cox proportional hazards regression models.
Factors (measured at the time of MI) that were considered
for inclusion in these models were: age, sex, mode of
HIV acquisition, ethnicity, cohort, calendar year of MI,
current/cumulative exposure to antiretroviral therapy
(ART), prior AIDS diagnosis, CD4þ cell count, viral
load, smoking status, body mass index, family history of
CVD, hypertension (SBP >140mmHg and/or DBP
>90mmHg and/or on ACEIs or other antihypertensives
[26]), dyslipidaemia [total cholesterol (TC) 6.2mmol/l
or hyperdensity lipoprotein cholesterol (HDL-C)
0.9mmol/l or TC:HDL-C ratio 6.5 or receipt of
LLDs [26]], prior diabetes, prior stroke (both centrally
validated), prior MI and Framingham risk score. Factors
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that were associated with mortality in univariable analyses
(P< 0.1) were considered for inclusion in the multi-
variable model with a stepwise selection procedure used
to identify the factors that would be retained in the
model. The resulting model was then further adjusted for
interventions received in the first month after MI.
Factors associated with short-term mortality (deaths
occurring within the first 31 days after MI) were
identified using unadjusted/adjusted logistic regression
models with potential confounders selected as described
above. All models included calendar year as this was our
exposure of interest; analyses were restricted to individ-
uals with at least 1 month of follow-up (or those who had
died within the first month) to avoid introducing bias due
to variable follow-up times over this first month. Analyses
were performed separately for CVD/non-CVD related
deaths and stratified by calendar period.
Results
Characteristics of individuals at time of an MI
One thousand and eight D:A:D participants experienced
an MI over the period 1999–2014. The majority were
men (90.8%), the median [interquartile range (IQR)] age
at the time of MI was 51 (44, 58) years, and 55.9% were of
white ethnicity. The most prevalent CVD risk factors
seen were dyslipidemia (66.6%), current smoking (53.3%)
and hypertension (42.5%); around one in three indivi-
duals with an MI were known to be receiving LLDs
(35.5%) and one in four (26.4%) antihypertensives. At the
time of MI, 90.4% of the individuals were on ARTwith
only 2.7% being antiretroviral-naive (the remaining 6.9%
had previously received ART). The median (IQR)
10-year predicted CVD risk (based on the Framingham
score, available in 82.1% of those with an MI) was 14.1%
(8.9%, 20.7%); 58.2% of the individuals with an available
score had a moderate to high predicted risk of more than
10% (Table 1).
The number of MIs in each year is shown in Table 1. The
proportion of MIs in each year that was classified as
definite MIs was stable (58.9% in 1999–2002 to 60.4%
in 2011–2014). There were some changes in the
characteristics of individuals that experienced an MI
over the same period; the median age increased from 48
to 54 years, the proportion of current smokers increased
from 49.5 to 54.6%, and there were increases in the
proportions of individuals who had dyslipidemia,
hypertension and a moderate/high Framingham risk
score. In more recent years, a higher proportion of
individuals were on ART, had a suppressed viral load and
a higher CD4þ cell count (Table 1).
Interventions at or after time of MI
Overall, 581 (57.6%) of the study participants underwent
an ANG, 87 (8.6%) a CABG and 7 (0.7%) an END
following their MI, with 620 (61.5%) of participants
undergoing at least one ICP after MI. Just under two-
thirds, 370 (59.7%) of the ICPs were carried out on the
same day as the MI, 168 (27.1%) were carried out within
the first 31 days and the remaining 82 (13.2%) were
carried out more than 31 days after MI. LLDs were
initiated after MI in 397 of 650 participants (61.1%) who
were not already receiving them, with 254 (63.9%) of
these initiating LLDs within the first month after MI;
antiplatelets, ACEIs and antihypertensives were initiated
in 477 of 758 participants (62.9%) [362 (75.9%) within
the first month after MI], 354 of 810 participants (43.7%)
[202 (57.1%) within the first month after MI] and 399 of
742 participants (53.8%) [265 (66.5%) within the first
month after MI], respectively. In general, there seemed to
be an increasing trend over time in the use of medical
interventions prior to MI and in all interventions after MI
(Fig. 1).
Causes of death following MI
Over a median (IQR) follow-up time of 42.7 (9.6, 84.0)
months after their MI, 117 of the 1008 HIV-positive
individuals (11.6%) experienced a further MI and 339
(33.6%) died.
Of the deaths that occurred, 145 (42.8% of deaths, 14.4%
of all individuals) were on the same day as the MI, 37
(10.7% of deaths, 3.7% of all individuals) were within the
first month after the MI, and 157 (46.3% of deaths, 15.6%
of all individuals) were more than 31 days after MI. The
proportion of deaths that was due to CVD varied
according to the timing of the death relative to the MI:
129 (89%) and 33 (87.1%) of deaths that occurred on the
same day as the MI or within the first month after MI
were due to CVD respectively, whereas only 59 (37.6%)
of deaths that occurred more than 31 days after MI were
due to CVD (Fig. 2a). In total, 182 deaths occurred in the
first month after MI yielding an overall short-term
mortality rate of 18.1%; this rate dropped from 26.6% in
1999–2002 to 8.4% in 2011–2014. The overall
proportion of individuals dying from any CVD dropped
from 72.6% in 1999–2002 to 40.9% in 2011–2014,
whereas the proportion of individuals dying from causes
other than CVD following their MI increased over the
same period; major contributing causes being HIV/
AIDS, non-AIDS cancers, bacterial infections, lung
disease and unknown causes (Fig. 2b).
Factors associated with overall mortality
following MI
In unadjusted proportional hazards regression models,
factors associated with increased mortality were: older
age; injection drug use (IDU) mode of HIV acquisition;
black African ethnicity; prior AIDS; higher viral load;
diabetes; prior MI; and prior stroke. Higher CD4þ cell
count, later calendar year of MI and family history of
CVD were all associated with decreased mortality (data
not shown). In a multivariable model, all these factors
Short-term mortality after myocardial infarction Hatleberg et al. 1585
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remained independently associated with mortality except
black African ethnicity, prior AIDS and higher viral
load.
In order to investigate the potential impact of inter-
ventions received in the first month post-MI, the analysis
was repeated after excluding individuals who did not
survive or remain under follow-up beyond the first
month. Factors remaining independently associated
with mortality in this multivariable model were: older
age; prior AIDS; higher viral load; previousMI; diabetes;
and later calendar year (Table 2). Additional adjustment
for the interventions received in the first month had
only minor effects on the associations between these
factors and mortality, although it led to an attenuation
of the calendar year association from hazard rate
0.95 [95% confidence interval (CI) 0.89, 1.00] per
later year to 0.98 (95% CI 0.92, 1.04) per later year
(Table 2). Of the interventions themselves, only the
ICPs demonstrated a strong association with mortality in
this model.
Factors associated with short-term mortality
following MI
In unadjusted logistic regression models, the factors
associated with an increased risk of short-term mortality
were: IDU mode of HIV acquisition; black African
ethnicity; prior AIDS; higher viral load and prior stroke.
A family history of CVD, higher CD4þ cell count and
later calendar year were associated with decreased risk of
short-term mortality (data not shown). In a multivariable
model excluding interventions during the first month
after MI, IDU mode of HIV acquisition, higher CD4þ
cell count, family history of CVD and prior stroke
continued to be associated with short-term mortality, and
again there was a strong calendar year effect (Table 3).
When including interventions received in the first month
following MI, ICPs, LLDs and antiplatelets were
significantly associated with decreased risk of short-term
mortality, and this led to attenuations of the associations
with prior stroke [from odds ratio (OR) 3.24 (95% CI
1.61, 6.53) to 2.08 (95% CI 0.90, 4.84)] and family
history of CVD [from 0.46 (95% CI 0.25, 0.86) to 0.61
(95% CI 0.30, 1.24)]. The calendar year effect was
attenuated from 0.88 (95%CI 0.83, 0.93) to 0.97 (95%CI
0.91, 1.02) in this adjusted model (Table 3).
Discussion
We observed an improvement in survival after MI in the
D:A:D cohort over the last 15 years. Those who
experienced an MI continued to be individuals with a
high CVD risk profile, although their HIV-related health
indicators improved. There was an increase in the use of
interventions at the time of, and shortly after an MI, and
we observed a reduction in the short-term mortality rate
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following MI. Predictors of decreased short-term
mortality were higher CD4þ cell count, family history
of CVD, later year of MI and the receipt of antiplatelets,
LLDs and ICPs. When adjusting for CVD interventions
in the first month after MI, the calendar year effect on
short term-mortality was attenuated, arguing that the
observed change is mainly driven by the increased use of
interventions in recent years.
Within the D:A:D Study, we have seen a gradual
reduction in the risk of MI over time in line with findings
from the general population [27], and in the present study,
we observed some changes in the characteristics of
individuals experiencing an MI. As previously docu-
mented [28], the key demographic characteristics in
individuals at the time of MI were male sex and older age,
and other CVD risk factors were dominated by
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Fig. 1. Use of invasive procedures and drug interventions before and in the first month after MI, stratified by calendar period.
ACEIs angiotensin-converting enzyme inhibitors; ICPs, invasive cardiovascular procedures; LLDs, lipid-lowering drugs; MI,
myocardial infarction. Carotid angioplasty, coronary artery bypass graft, carotid endarterectomy.
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modifiable factors, i.e. current smoking, hypertension
and dyslipidemia. There were notable increases in the
proportions of people with an MI who were known to
have dyslipidemia and/or hypertension, and slight
increases in the proportions of individuals with a
moderate to high Framingham risk score. Most likely
this reflects improved monitoring of lipids and blood
pressure in the cohorts rather than any change over time
in the risk conferred by these conditions, as well as
increased awareness and monitoring of CVD risk and
gradual aging of individuals in the cohort, respectively.
These findings are consistent with earlier studies
[6,15,29,30,31]. The proportion of individuals with an
MI who were on ART with a suppressed viral load
increased, as did the median CD4þ cell count. This
improvement in HIV-related health indices amongst
participants in the study has probably contributed to the
improved survival seen over the study period. The use of
improved antiretroviral drugs with fewer metabolic side-
effects in recent years may also partly explain the
improved survival, although we did not specifically
investigate this in our study.
The HIV-positive population has changed significantly
over the last decade as HIV/AIDS-related morbidity and
mortality rates have declined and other causes of death
have become increasingly common [32,33,34]. The all-
cause mortality rate in the D:A:D Study population fell
from 17.5/1000 PYRS in 1999/2000 to 9.1 /1000
PYRS in 2009–2011; the leading causes of death being
AIDS-and HIV-related causes, non-AIDS defining
cancers, liver disease and CVD [32]. The crude CVD
incidence mortality rate fell from 1.8/1000 PYRS to
0.9 /1000 PYRS from 1999 to 2011 [32]. In our analysis,
nearly 90% of individuals who died within the first
month after MI died of CVD-related causes. Although
the short-term mortality rates after MI dropped, our
findings emphasize the importance of continued
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Table 2. Factors associated with mortality following MI, conditioned on the fact that patient survives for at least one month – multivariable
modela.
Factor
Excluding interventions in first month Including interventions in first month
Hazard rate (95% CI) P-value Hazard rate (95% CI) P-value
Age (/10 years older) 1.18 (1.09, 1.28) 0.0001 1.13 (1.05, 1.23) 0.002
AIDS 1.45 (1.05, 2.01) 0.02 1.42 (1.02, 1.98) 0.04
CD4þ count (/50 cells/ml increment) 0.97 (0.94, 1.00) 0.05 0.96 (0.93, 1.00) 0.03
HIV RNA (/log10 increment) 1.19 (1.03, 1.38) 0.0001 1.19 (1.02, 1.38) 0.03
Previous MI 1.85 (1.14, 3.00) 0.02 1.63 (1.00, 2.67) 0.05
Previous diabetes 2.16 (1.46, 3.19) 0.01 2.13 (1.43, 3.16) 0.0002
Year of MI (/ later year) 0.95 (0.89, 1.00) 0.007 0.98 (0.92, 1.04) 0.50
Interventions in first month
Anti-platelets n/a 0.72 (0.44, 1.17) 0.18
ACEIs n/a 1.07 (0.65, 1.76) 0.80
Anti-hypertensives n/a 0.76 (0.45, 1.29) 0.31
LLDs n/a 0.93 (0.58, 1.49) 0.76
ICPs n/a 0.44 (0.31, 0.63) 0.0001
ACEIs, angiotensin converting enzyme- inhibitors; ICPs, invasive cardiovascular procedures; LLDs, lipid-lowering drugs;MI, myocardial infarction.
aAlso adjusted for cohort.
Table 3. Factors associated with short-term mortality following MI –multivariable model.a
Factor
No adjustment for interventions
in first month
Adjustment for interventions
in first month
Odds ratio (95% CI), P-value Odds ratio (95% CI) P-value
IDU 1.90 (1.20, 2.99) 0.006 1.66 (0.98, 2.83) 0.06
CD4þ count (/50 cells/ml increment) 0.93 (0.90, 0.96) 0.0001 0.92 (0.89, 0.96) 0.0001
Family history of CVD 0.46 (0.25, 0.86) 0.01 0.61 (0.30, 1.24) 0.17
Stroke 3.24 (1.61, 6.53) 0.001 2.08 (0.90, 4.84) 0.09
Year of MI (/later year) 0.88 (0.83, 0.93) 0.0001 0.97 (0.91, 1.02) 0.23
Interventions in first month
Anti-platelets n/a 0.09 (0.03, 0.31) 0.0001
ACEIs n/a 0.45 (0.12, 1.66) 0.23
Anti-hypertensives n/a 0.25 (0.05, 1.18) 0.08
LLDs n/a 0.27 (0.08, 0.95) 0.04
ICPs n/a 0.07 (0.04, 0.13) 0.0001
ACEIs, angiotensin converting enzyme- inhibitors; CVD, cardiovascular disease; ICPs, invasive cardiovascular procedures; LLDs, lipid-lowering
drugs; MI, myocardial infarction.
aAlso adjusted for cohort.
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improvement of the management of CVD in HIV-
positive individuals. The magnitude of the reduction in
short-term mortality after MI over time in this study
(26.6 to 8.4%) is similar to the reductions seen in the
general population over the last 15–20 years, although
mortality is still higher in our study population compared
with equally youngHIV-negative individuals (<65 years)
[1].
The clear improvements in survival outcomes in our
study, particularly short-term mortality in the month
following MI, appeared to be largely driven by improved
clinical management. The use of ICPs increased by 35%
from 1999–2002 to 2011–2014; where ICPs were used,
angioplasties in particular tended to be undertaken on the
same day as the MI. In some studies, HIV-positive
individuals have previously been found to have a higher
rate of recurrent MIs and to more frequently undergo
urgent angioplasties [18,28,35,36,37]. The proportion of
recurrent MIs in the study was 11.6%; which is higher
compared with previous findings from the general
population (8.9% in 2010) [38]. We were unable to
systematically evaluate the type of MI and degree of vessel
disease, but the relatively young median age of the study
participants at the time of MI may indicate that a higher
proportion may have had a ST-elevated myocardial
infarction (STEMI), as an inverse relationship has been
demonstrated in men in the general population between
age and the likelihood of the MI being a STEMI [39]. A
STEMI often requires urgent invasive treatment, possibly
partly explaining the increased use of ICPs seen, and
the latter may also be explained by the improvement in
HIV-related characteristics, increasing the eligibility of
individuals to undergo ICPs than was the case in earlier
years.
We reported an increasing trend in the use of certain
drugs following MI over time; LLDs and antiplatelets
were the drugs most frequently started in those not
already on these medications, arguing that secondary
medical prophylaxis of CVD seem to be somewhat
improving. The effectiveness and quality of CVD drugs
may have also improved in more recent years, possibly
contributing to improved survival.
In our study, we found that the calendar year effect on
decreased short-term mortality seemed to be mediated
through the increased use of CVD interventions in recent
years, as its effect was attenuated after adjusting for
interventions received in the first month after MI.
Adjustment for interventions did not influence the
decreased short-term mortality risk associated with a
higher CD4þ cell count. Similarly, adjustment for
interventions received in the first month after MI also
resulted in an attenuation of the calendar effect on long-
term mortality, again suggesting that this effect was
mediated through the use of interventions. Adjusting for
interventions in the first month following MI did,
however, not influence the predictors of increased long-
term mortality, whereas the associations between stroke,
family history of CVD and IDUmode of HIVacquisition
and short-term mortality were weakened, suggesting also
these associations to be partly influenced by the use
of interventions.
One study previously demonstrated that HIV status
influences long-term risk for adverse outcomes after MI
by being an independent predictor for long-term risk of
heart failure [40]. In our study, we were unable to assess
the impact of HIV per se, but found that survival
substantially improved in line with improvements in the
CD4þ cell count, which was an independent predictor
for decreased short-term mortality. The current longer-
term outcomes after MI need to be further explored in
our study population.
Although we demonstrated that an increased number of
HIV-positive individuals now receive invasive and
medical interventions after MI, there is still a proportion
of individuals surviving their MIs who do not appear to
receive these interventions. One possible explanation is
under- or delayed ascertainment of such interventions.
However, findings from our annual monitoring process
suggest that the number of missed clinical events in the
D:A:D Study is very low. Complicating co-morbidities
influencing the eligibility of a person to undergo ICPs, the
type of MI, and differences in clinical practices at different
medical centresmayalso play a role. Further, theuseof drug
interventions in those with HIV is often challenging given
the possibilityof drug–drug interactionswith antiretroviral
drugs [6,41], which may limit CVD treatment options.
Finally, previous findings have reported that there is an
inverse relationship between in-hospital mortality after MI
and the number of CVD risk factors present at the time of
MI [42], indicating that low-risk individuals may therefore
have other, as yet unidentified, factors which may
contribute to progressive disease [42].
Some limitations to our study need to be acknowledged.
The use of nonmedical interventions (e.g. dietary advice,
advice on smoking cessation or exercise) is not captured
systematically in the D:A:D Study, and may have
contributed to improved survival. Further, it is compli-
cated to evaluate the effect of relatively infrequent
interventions, such as the use of ICPs, in an observational
cohort as analyses of these interventions are likely to be
affected by time-varying confounding and standard
analytical methods are likely to give biased estimates.
Finally, we did not evaluate the status of interventions at
time of any recurrent MI although these may also have
changed over time.
Conclusion
In this study, we demonstrated improvements in short-
term survival after MI in HIV-positive individuals, which
appeared to be largely driven by increased use of drug
1590 AIDS 2016, Vol 30 No 10
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interventions and ICPs. However, some individuals are
still not receiving these interventions despite a high CVD
risk profile. Our findings suggest that preventive measures
need to be further explored, with targeted focusing on
modifiable risk factors including smoking cessation,
control of hypertension, dyslipidemia and diabetes as well
as appropriate choice of antiretroviral drugs.
Acknowledgements
Author contributions: L.R., J.D.L. and C.S. developed
the initial analysis protocol. L.R and C.I.H. performed
study co-ordination and prepared the datasets for analysis,
C.S. performed the statistical analysis. C.I.H. prepared the
first draft of the manuscript. All authors have provided
input at all stages of the project.
Funding: This work was supported by the Highly Active
Antiretroviral Therapy Oversight Committee (HAART-
OC), a collaborative committee with representation from
academic institutions, the European Agency for the
Evaluation ofMedicinal Products, the United States Food
and Drug Administration, the patient community, and
pharmaceutical companies with licensed anti-HIV drugs
in the European Union: AbbVie, Bristol-Myers Squibb,
Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc.
and Janssen Pharmaceuticals. Supported also by a grant
[grant number DNRF126] from the Danish National
Research Foundation (CHIP & PERSIMUNE); by a
grant from the Dutch Ministry of Health, Welfare and
Sport (ATHENA); by a grant from the Agence nationale
de recherches sur le sida et les he´patites virales [ANRS,
Action Coordonne´e no.7, Cohortes] to the Aquitaine
Cohort; The Australian HIV Observational Database
(AHOD) is funded as part of the Asia Pacific HIV
Observational Database, a program of The Foundation
for AIDS Research, amfAR, and is supported in part by a
grant from the U.S. National Institutes of Health’s
National Institute of Allergy and Infectious Diseases
(NIAID) [grant number U01-AI069907] and by uncon-
ditional grants from Merck Sharp & Dohme; Gilead
Sciences; Bristol-Myers Squibb; Boehringer Ingelheim
Roche; Pfizer; GlaxoSmithKline; Janssen Pharmaceuti-
cals. The Kirby Institute is funded by The Australian
Government Department of Health and Ageing, and is
affiliated with the Faculty of Medicine, The University of
New South Wales. By grants from the Fondo de
Investigacio´n Sanitaria [grant number FIS 99/0887]
and Fundacio´n para la Investigacio´n y la Prevencio´n del
SIDA en Espana˜ [grant number FIPSE 3171/00], to the
Barcelona Antiretroviral Surveillance Study (BASS); by
the National Institute of Allergy and Infectious Diseases,
National Institutes of Health [grants number
5U01AI042170-10, 5U01AI046362-03], to the Terry
Beirn Community Programs for Clinical Research on
AIDS (CPCRA); by grants from the BIOMED 1 [grant
number CT94-1637] and BIOMED 2 [grant number
CT97-2713] programs and the 5th framework program
[grant number QLK2-2000-00773], the 6th Framework
(LSHP-CT-2006-018632), and the 7th Framework
(FP7/2007-2013, EuroCoord no 260694) programmes
of the European Commission and unrestricted grants
by Janssen R&D, Merck and Co. Inc., Pfizer Inc.,
GlaxoSmithKline LLC [the participation of centres from
Switzerland is supported by The Swiss National Science
Foundation (Grant 108787)] to the EuroSIDA study; by
unrestricted educational grants of AbbVie, Bristol-Myers
Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer,
Janssen Pharmaceuticals to the Italian Cohort Naive to
Antiretrovirals (The ICONA Foundation); and by a grant
from the Swiss National Science Foundation (grant
#148522) to the Swiss HIV Cohort Study (SHCS).
The content of this publication is solely the responsibility
of the authors and does not necessarily represent the
official views of any of the institutions mentioned above.
D:A:D particpating cohorts: Aquitaine (France),
CPCRA (USA), Nice (France), ATHENA (The Nether-
lands), EuroSIDA (Europe, Israel and Argentina), SHCS
(Switzerland), AHOD (Australia), HIV-BIVUS (Swe-
den), St. Pierre Brussels Cohort (Belgium), BASS
(Spain), The ICONA Foundation (Italy).
D:A:D Steering Committee: Names marked with ,
Chair with #
Members of the D:A:D SC from the Oversight
Committee: B. Powderly, N. Shortman, C. Moeck-
linghoff , G. Reilly, X. Franquet. D:A:D Central
Coordination: C.I. Hatleberg, L. Ryom, C.A. Sabin, D.
Kamara, C. Smith, A. Phillips, A. Mocroft, A. Bojesen,
J. Nielsen, C. Matthews, D. Raben, J.D. Lundgren.
D:A:D data managers: R. Salbøl Brandt (coordinator), M.
Rickenbach, I. Fanti, E. Krum, M. Hillebregt, S. Geffard,
Jaohar Mourabi, A. Sundstro¨m, M. Delforge, E. Fontas, F.
Torres, H. McManus, S. Wright, J. Kjær, Dennis
Kristensen. Verification of endpoints: A. Sjøl (CVD
primary endpoint), P. Meidahl (oncology, new endpoint),
J. Helweg-Larsen (hematology, new endpoint), J. Schmidt
Iversen (nephrology, new endpoint). Kidney working
group: L. Ryom, A. Mocroft, O. Kirk, P. Reiss, M.
Ross, C.A. Fux, P. Morlat, O. Moranne, A.M. Kesselring,
D.A.Kamara, C. Smith, J.D. Lundgren.Mortality working
group: C. Smith, L. Ryom, A. Phillips, R. Weber, P.
Morlat, C. Pradier, P. Reiss, N. Friis-Møller, J.
Kowalska, J.D. Lundgren. Cancer working group: C.
Sabin, M. Law, A. d’Arminio Monforte, F. Dabis, M.
Bruyand, P. Reiss, C. Smith, D.A. Kamara, M Bower, G.
Fa¨tkenheuer, A.Grulich, L.Ryom, J.D. Lundgren.
The members of the 11 cohorts are as follows:
ATHENA (AIDS Therapy Evaluation Project Nether-
lands) – Central coordination: P. Reiss, S. Zaheri, M
Short-term mortality after myocardial infarction Hatleberg et al. 1591
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Hillebregt, L.Gras. Participating physicians (¤Site coor-
dinating physicians) – Academisch Medisch Centrum bij
de Universiteit van Amsterdam, Amsterdam: Prof. Dr
J.M. Prins¤, Prof. Dr T.W. Kuijpers, Drs H.J. Scherpbier,
J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried,
Prof. Dr P. Reiss¤, Prof. Dr T. van der Poll, Dr F.J.B.
Nellen, Prof. Dr J.M.A. Lange, Drs S.E. Geerlings, M.
van Vugt, D. Pajkrt, J.C. Bos, M. van der Valk, M.L.
Grijsen, W.J. Wiersinga, A. Goorhuis, J.W.R. Hovius.
Academisch Ziekenhuis Maastricht, Maastricht: Drs S.
Lowe¤, A. Oude Lashof, D. Posthouwer. Catharina-
ziekenhuis, Eindhoven: Drs M.J.H. Pronk¤, H.S.M.
Ammerlaan. ErasmusMedisch Centrum,Rotterdam: Drs
M.E. van der Ende¤, T.E.M.S. de Vries-Sluijs, C.A.M.
Schurink, J.L. Nouwen, A. Verbon, B.J.A. Rijnders,
E.C.M. van Gorp, M. van der Feltz. Erasmus Medisch
Centrum–Sophia, Rotterdam: Drs G.J.A. Driessen,
A.M.C. van Rossum. Flevoziekenhuis. Almere: Dr J.
Branger¤. HagaZiekenhuis, Den Haag: Drs E.F. Schip-
pers¤, C. van Nieuwkoop, E.P. van Elzakker. Isala
Klinieken, Zwolle: Drs P.H.P. Groeneveld¤, J.W.
Bouwhuis. Kennemer Gasthuis: Dr R. Soetekouw¤,
Prof. Dr R.W. ten Kate. Leids Universitair Medisch
Centrum, Leiden: Dr F.P. Kroon¤, Prof. Dr J.T. van
Dissel, Drs S.M. Arend, M.G.J. de Boer, H. Jolink,
H.J.M. ter Vollaard, M.P. Bauer. Maasstadziekenhuis,
Rotterdam: Drs J.G. den Hollander¤, K. Pogany.
Medisch Centrum Alkmaar, Alkmaar: Dr G. van
Twillert¤, Dr W. Kortmann¤, Dr J.W.T. Cohen Stuart,
Dr B.M.W. Diederen. Medisch Centrum Haaglanden,
Den Haag: Dr E.M.S. Leyten¤, Dr L.B.S. Gelinck.
Medisch SpectrumTwente, Enschede: Dr G.J. Kootstra¤,
Dr C.E. Delsing. Onze Lieve Vrouwe Gasthuis,
Amsterdam: Prof. Dr K. Brinkman¤, Dr W.L. Blok,
Dr P.H.J. Frissen, Dr W.E.M. Schouten, Dr G.E.L. van
den Berk. Sint Elisabeth Ziekenhuis, Tilburg: Dr M.E.E.
van Kasteren¤, Dr A.E. Brouwer. Sint Lucas Andreas
Ziekenhuis, Amsterdam: Dr J. Veenstra¤, Dr K.D.
Lettinga. Slotervaartziekenhuis, Amsterdam: Dr J.W.
Mulder¤, Dr S.M.E. Vrouenraets, Dr F.N. Lauw.
Stichting Medisch Centrum Jan van Goyen, Amsterdam:
Dr A. van Eeden¤, Dr D.W.M. Verhagen. Universitair
Medisch Centrum Groningen, Groningen: Dr H.G.
Sprenger¤, Dr R. Doedens, Dr E.H. Scholvinck, Dr S.
van Assen, Dr W.F.W. Bierman. Universitair Medisch
Centrum Sint Radboud, Nijmegen: Dr P.P. Koopmans¤,
Dr M. Keuter, Dr A.J.A.M. van der Ven, Dr H.J.M. ter
Hofstede, Dr A.S.M. Dofferhoff, Dr AWarris, Dr R. van
Crevel. Universitair Medisch Centrum Utrecht, Utrecht:
Prof. Dr A.I.M. Hoepelman¤, Dr T. Mudrikova, Dr
M.M.E. Schneider, Dr P.M. Ellerbroek, Dr J.J. Oos-
terheert, Dr J.E. Arends, Dr M.W.M. Wassenberg, Dr
R.E. Barth. Vrije Universiteit Amsterdam, Amsterdam:
Dr M.A. van Agtmael¤, Dr R.M. Perenboom, Dr F.A.P.
Claessen, Dr M. Bomers, Dr E.J.G. Peters. Wilhelmina
Kinderziekenhuis, Utrecht: Dr S.P.M. Geelen, Dr T.F.W.
Wolfs, Dr L.J. Bont. Ziekenhuis Rijnstate, Arnhem: Dr
C. Richter¤, Dr J.P. van der Berg, Dr E.H. Gisolf.
Admiraal De Ruyter Ziekenhuis, Vlissingen: Dr M. van
den Berge¤, Dr A. Stegeman. Medisch Centrum
Leeuwarden, Leeuwarden: Dr M.G.A. van Vonderen¤,
Dr D.P.F. van Houte. Medisch Centrum Zuiderzee,
Lelystad: Dr S. Weijer¤, Dr R. el Moussaoui. Sint
Elisabeth Hospitaal, Willemstad – Curac¸ao: Dr C.
Winkel, Dr F. Muskiet, Dr Durand, Dr R. Voigt.
Aquitaine Cohort (France) Coordination: F. Bonnet, F.
Dabis. Scientific committee: F. Bonnet, S. Bouchet, D.
Breilh, G. Cheˆne, F. Dabis, M. Dupon, H. Fleury, V.
Gaborieau, D. Lacoste, D. Malvy, P. Mercie´, P. Morlat, D.
Neau, I. Pellegrin, JL. Pellegrin, S. Reigadas, S.
Tchamgoue´. Epidemiology and Methodology: M.
Bruyand, G. Cheˆne, F. Dabis, C. Fagard, S. Lawson-
Ayayi, L. Richert, R. Thie´baut, L. Wittkop. Infectious
Diseases and Internal Medicine: K. Andre´, F. Bonnet, N.
Bernard, L. Caune`gre, C. Cazanave, J. Ceccaldi, I.
Chossat, C. Courtault, FA. Dauchy, S. De Witte, D.
Dondia, M. Dupon, A. Dupont, P. Duffau, H. Dutronc,
S. Farbos, I. Faure, V. Gaborieau, Y. Gerard, C. Greib, M.
Hessamfar-Joseph, Y. Imbert, D. Lacoste, P. Lataste, E.
Lazaro, D. Malvy, J. Marie, M. Mechain, JP. Meraud, P.
Mercie´, E. Monlun, P. Morlat, D. Neau, A. Ochoa, JL.
Pellegrin, M. Pillot-Debelleix, T. Pistone, I. Raymond,
MC. Receveur, P. Rispal, L. Sorin, S. Tchamgoue´, C.
Valette, MA. Vandenhende, MO. Vareil, JF. Viallard, H.
Wille, G. Wirth. Immunology: J.F. Moreau, I. Pellegrin.
Virology: H. Fleury, M.E. Lafon, S. Reigadas, P.
Trimoulet. Pharmacology: S. Bouchet, D. Breilh, F.
Haramburu, G. Miremont-Salame´. Data collection,
Project Management and Statistical Analyses: M.J.
Blaizeau, I. Crespel, M. Decoin, S. Delveaux, F. Diarra,
C. D’Ivernois, C. Hanappier, D. Lacoste, S. Lawson-
Ayayi, O. Leleux, F. Le Marec, E. Lenaud, J. Mourali, E.
Pernot, A. Pougetoux, B. Uwamaliya-Nziyumvira, A.
Tsaranazy, A. Valdes. IT department and eCRF devel-
opment: V. Conte, I. Louis, G. Palmer, V. Sapparrart, D.
Touchard. AHOD (Australian HIV Observational Data-
base, Australia): Central coordination: M. Law , K.
Petoumenos, H. McManus, S. Wright, C. Bendall
(Sydney, New South Wales). Participating physicians
(city, state): R. Moore, S. Edwards, J. Hoy, K. Watson, N.
Roth, J. Nicholson (Melbourne, Victoria); M. Bloch, T.
Franic, D. Baker, R. Vale, A. Carr, D. Cooper (Sydney,
New South Wales); J. Chuah, M. Ngieng (Gold Coast,
Queensland), D. Nolan, J. Skett (Perth, Western
Australia). BASS (Spain): Central coordination: G. Calvo,
F. Torres, S. Mateu (Barcelona). Participating physicians
(city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del
Cacho, J. Cadafalch, M. Fuster (Barcelona); C. Codina,
G. Sirera, A. Vaque´ (Badalona). The Brussels St. Pierre
Cohort (Belgium). Coordination: S. De Wit, N.
Clumeck, M. Delforge, C. Necsoi. Participating phys-
icians: N. Clumeck, S. De Wit, A.F. Gennotte, M.
Gerard, K. Kabeya, D. Konopnicki, A. Libois, C. Martin,
M.C. Payen, P. Semaille, Y. Van Laethem. CPCRA
(USA): Central coordination: J. Neaton, G. Bartsch,
W.M. El-Sadr, E. Krum, G. Thompson, D. Wentworth.
1592 AIDS 2016, Vol 30 No 10
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Participating physicians (city, state): R. Luskin-Hawk
(Chicago, Illinois); E. Telzak (Bronx, New York); W.M.
El-Sadr (Harlem, New York); D.I. Abrams (San
Francisco, California); D. Cohn (Denver, Colorado);
N. Markowitz (Detroit, Michigan); R. Arduino (Hous-
ton, Texas); D. Mushatt (New Orleans, Louisiana); G.
Friedland (New Haven, Connecticut); G. Perez (New-
ark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania);
E. Fisher (Richmond, Virginia); F. Gordin (Washington,
DC); L.R. Crane (Detroit, Michigan); J. Sampson
(Portland, Oregon); J. Baxter (Camden, New Jersey).
EuroSIDA (multinational) Coordinating Centre: J
Lundgren#, O Kirk, A Mocroft, A Cozzi-Lepri, D
Grint, D Podlekareva, J Kjær, L Peters, J Reekie, J
Kowalska, J Tverland, A H Fischer, J Nielsen Participat-
ing countries and physicians Argentina: (M Losso), C
Elias, Hospital JM Ramos Mejia, Buenos Aires. Austria:
(N Vetter), Pulmologisches Zentrum der Stadt Wien,
Vienna; R Zangerle, Medical University Innsbruck,
Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarus
State Medical University, Minsk, VM Mitsura, Gomel
State Medical University, Gomel; O Suetnov, Regional
AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De
Wit, M Delforge, Saint-Pierre Hospital, Brussels; R
Colebunders, Institute of Tropical Medicine, Antwerp; L
Vandekerckhove, University Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki
Centar Univerziteta Sarajevo, Sarajevo. Bulgaria: (K
Kostov), Infectious Diseases Hospital, Sofia. Croatia: (J
Begovac), University Hospital of Infectious Diseases,
Zagreb. Czech Republic: (L Machala), D Jilich, Faculty
Hospital Bulovka, Prague; D Sedlacek, Charles Univer-
sity Hospital, Plzen. Denmark: (J Nielsen), G Kron-
borg,T Benfield, M Larsen, Hvidovre Hospital,
Copenhagen; J Gerstoft, T Katzenstein, A-B E Hansen,
P Skinhøj, Rigshospitalet, Copenhagen; C Pedersen,
Odense University Hospital, Odense; L Ostergaard,
Skejby Hospital, Aarhus. Estonia: (K Zilmer), West-
Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakku-
sosakond Siseklinik, Kohtla-Ja¨rve. Finland: (M Ristola),
Helsinki University Central Hospital, Helsinki. France:
(C Katlama), Hoˆpital de la Pitie´-Salpe´tie`re, Paris; J-P
Viard, Hoˆpital Necker-Enfants Malades, Paris; P-M
Girard, Hospital Saint-Antoine, Paris; JM Livrozet,
Hoˆpital Edouard Herriot, Lyon; P Vanhems, University
Claude Bernard, Lyon; C Pradier, Hoˆpital de l’Archet,
Nice; F Dabis, D Neau, Unite´ INSERM, Bordeaux.
Germany: (J Rockstroh), Universita¨ts Klinik Bonn; R
Schmidt, Medizinische Hochschule Hannover; J van
Lunzen, ODegen, UniversityMedical Center Hamburg-
Eppendorf, Infectious Diseases Unit, Hamburg; HJ
Stellbrink, IPM Study Center, Hamburg; S Staszewski,
JW Goethe University Hospital, Frankfurt; Markus
Bickel, Medizinische Poliklinik, Munich; G. Fa¨tken-
heuer, Universita¨t Ko¨ln, Cologne. Greece: (J Kosmidis),
P Gargalianos, G Xylomenos, J Perdios, Athens General
Hospital; G Panos, A Filandras, E Karabatsaki, 1st IKA
Hospital; H Sambatakou, Ippokration Genereal Hospital,
Athens. Hungary: (D Banhegyi), Szent La´slo´ Hospital,
Budapest. Ireland: (F Mulcahy), St. James’s Hospital,
Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov
Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam
Medical Center, Haifa; S Maayan, Hadassah University
Hospital, Jerusalem. Italy: (S Vella), Istituto Superiore di
Sanita`, Rome; R Esposito, I Mazeu, C Mussini,
Universita` Modena, Modena; C Arici, Ospedale Riuniti,
Bergamo; R Pristera, Ospedale Generale Regionale,
Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria
Annunziata, Firenze; V Vullo, M Lichtner, University di
Roma la Sapienza, Rome; A Chirianni, E Montesarchio,
MGargiulo, Presidio Ospedaliero ADCotugno, Monaldi
Hospital, Napoli; G Antonucci, A Testa, P Narciso, C
Vlassi, M Zaccarelli, Istituto Nazionale Malattie Infettive
Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N
Gianotti, Ospedale San Raffaele, Milan; M Galli, A
Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte,
Istituto Di Clinica Malattie Infettive e Tropicale, Milan.
Latvia: (B Rozentale), I Zeltina, Infectology Centre of
Latvia, Riga. Lithuania: (S Chaplinskas), Lithuanian
AIDS Centre, Vilnius. Luxembourg: (R Hemmer), T
Staub, Centre Hospitalier, Luxembourg. Netherlands: (P
Reiss), Academisch Medisch Centrum bij de Uni-
versiteit van Amsterdam, Amsterdam. Norway: (V
Ormaasen), A Maeland, J Bruun, Ulleva˚l Hospital, Oslo.
Poland: (B Knysz) J Gasiorowski, Medical University,
Wroclaw; A Horban, E Bakowska, CentrumDiagnostyki
i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak,
Medical University, Bialystok; A Boron-Kaczmarska, M
Pynka, M Parczewski, Medical Univesity, Szczecin; M
Beniowski, E Mularska, Osrodek Diagnostyki i Terapii
AIDS, Chorzow; H Trocha, Medical University, Gdansk;
E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki
Szpital Specjalistyczny, Lodz. Portugal: (F Antunes), M
Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K
Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez,
Hospital Curry Cabral, Lisbon. Romania: (D Duicu-
lescu), Spitalul de Boli Infectioase si Tropicale: Dr Victor
Babes, Bucarest. Russia: (A Rakhmanova), Medical
Academy Botkin Hospital, St Petersburg; N Zakharova,
St Petersburg AIDS Centre, St Peterburg; S Buzunova,
Novgorod Centre for AIDS, Novgorod. Serbia: (D
Jevtovic), The Institute for Infectious and Tropical
Diseases, Belgrade. Slovakia: (M Mokra´sˇ), D Stanekova´,
De´rer Hospital, Bratislava. Slovenia: (J Tomazic),
University Clinical Centre Ljubljana, Ljubljana. Spain:
(J Gonza´lez-Lahoz), V Soriano, P Labarga, J Medrano,
Hospital Carlos III, Madrid; S Moreno, JM Rodriguez,
Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R
Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias
i Pujol, Badalona; JM Gatell, JM Miro´, Hospital Clinic i
Provincial, Barcelona; P Domingo, M Gutierrez, G
Mateo, MA Sambeat, Hospital Sant Pau, Barcelona.
Sweden: (A Karlsson), Venhaelsan-Sodersjukhuset,
Stockholm; L Flamholc, Malmo¨ University Hospital,
Malmo¨. Switzerland: (B Ledergerber), R Weber,
University Hospital, Zu¨rich; P Francioli, M Cavassini,
Short-term mortality after myocardial infarction Hatleberg et al. 1593
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Centre Hospitalier Universitaire Vaudois, Lausanne; B
Hirschel, E Boffi, Hospital Cantonal Universitaire de
Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M
Battegay, L Elzi, University Hospital Basel. Ukraine: (E
Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev;
V Frolov, G Kutsyna, Luhansk State Medical University;
Luhansk; S Servitskiy, Odessa Region AIDS Center,
Odessa; M Krasnov, Kharkov State Medical University,
Kharkov. United Kingdom: (S Barton), St. Stephen’s
Clinic, Chelsea and Westminster Hospital, London; AM
Johnson, D Mercey, Royal Free and University College
London Medical School, London (University College
Campus); A Phillips, MA Johnson, A Mocroft, Royal
Free and University College Medical School, London
(Royal Free Campus); M Murphy, Medical College of
Saint Bartholomew’s Hospital, London; J Weber, G
Scullard, Imperial College School of Medicine at St.
Mary’s, London; M Fisher, Royal Sussex County
Hospital, Brighton; C Leen, Western General Hospital,
Edinburgh. HivBivus (Sweden): Central coordination: L.
Morfeldt, G. Thulin, A. Sundstro¨m. Participating
physicians (city): B. A˚kerlund (Huddinge); K. Koppel,
A. Karlsson (Stockholm); L. Flamholc, C. Ha˚kanga˚rd
(Malmo¨). The ICONA Foundation (Italy): Board of
directors: A d’ArminioMonforte, (Chair), M Andreoni,
G Angarano, A Antinori, F Castelli, R Cauda, GDi Perri,
M Galli, R Iardino, G Ippolito, A Lazzarin, CF Perno, F
von Schloesser, P Viale. Scientific secretary: A d’Arminio
Monforte, A Antinori, A Castagna, F Ceccherini-
Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C
Mussini, M Puoti. Steering committee: M Andreoni, A
Ammassari, A Antinori, C Balotta, A Bandera, P
Bonfanti, S Bonora, M Borderi, A Calcagno, L Calza,
MR Capobianchi, A Castagna, F Ceccherini-Silberstein,
A Cingolani, P Cinque, A Cozzi-Lepri, A d’Arminio
Monforte, A De Luca, A Di Biagio, E Girardi, N
Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S
Lo Caputo, G Madeddu, F Maggiolo, G Marchetti, S
Marcotullio, L Monno, C Mussini, S Nozza, M Puoti, E
Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A
Saracino,MZaccarelli. Statistical andmonitoring team: A
Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M
Shanyinde, ATavelli. Participating physicians and centres:
A Giacometti, A Costantini, S Mazzoccato (Ancona); G
Angarano, L Monno, C Santoro (Bari); F Maggiolo, C
Suardi (Bergamo); P Viale, E Vanino, G Verucchi
(Bologna); F Castelli, E Quiros Roldan, C Minardi
(Brescia); T Quirino, C Abeli (Busto Arsizio); PE
Manconi, P Piano (Cagliari); J Vecchiet, K Falasca
(Chieti); L Sighinolfi, D Segala (Ferrara); F Mazzotta, S
Lo Caputo (Firenze); G Cassola, C Viscoli, A Alessan-
drini, R Piscopo, GMazzarello (Genova); CMastroianni,
V Belvisi (Latina); P Bonfanti, I Caramma (Lecco); A
Chiodera, AP Castelli (Macerata); M Galli, A Lazzarin, G
Rizzardini, M Puoti, A d’Arminio Monforte, AL
Ridolfo, R Piolini, A Castagna, S Salpietro, L Carenzi,
MC Moioli, C Tincati, G. Marchetti (Milano); C
Mussini, C Puzzolante (Modena); A Gori, G Lapadula
(Monza); N Abrescia, A Chirianni, G Borgia, F Di
Martino, L Maddaloni, I Gentile, ROrlando (Napoli); F
Baldelli, D Francisci (Perugia); G Parruti, T Ursini
(Pescara); G Magnani, MA Ursitti (Reggio Emilia); R
Cauda, M Andreoni, A Antinori, V Vullo, A Cingolani,
G Baldin, L Gallo, E Nicastri, R Acinapura, M Capozzi,
R Libertone, S Savinelli, M Zaccarelli (Roma); M
Cecchetto, F Viviani (Rovigo); MS Mura, G Madeddu
(Sassari); A De Luca, B Rossetti (Siena); P Caramello, G
Di Perri, GCOrofino, S Bonora, M Sciandra (Torino); M
Bassetti, A Londero (Udine); G Pellizzer, V Manfrin
(Vicenza).
Nice HIV Cohort (France):
Central coordination: C. Pradier, E. Fontas, K. Dollet,
C. Caissotti. Participating physicians: P. Dellamonica, E.
Bernard, E. Cua, F. De Salvador-Guillouet, J. Durant, S.
Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost, B.
Prouvost-Keller, S. Pillet, P. Pugliese, V. Rahelinirina,
P.M. Roger. SHCS (Swiss HIV Cohort Study, Switzer-
land): V Aubert, M Battegay, E Bernasconi, J Bo¨ni, HC
Bucher, C Burton-Jeangros, A Calmy, M Cavassini, G
Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer
(Chairman of the Clinical and Laboratory Committee),
CA Fux, M Gorgievski, H Gu¨nthard (President of the
SHCS), D Haerry (deputy of ‘‘Positive Council’’), B
Hasse, HH Hirsch, M Hoffmann, I Ho¨sli, C Kahlert, L
Kaiser, O Keiser, T Klimkait, R Kouyos, H Kovari, B
Ledergerber, G Martinetti, B Martinez de Tejada, K
Metzner, N Mu¨ller, D Nadal, D Nicca, G Pantaleo, A
Rauch (Chairman of the Scientific Board), S Regenass,
M Rickenbach (Head of Data Center), C Rudin
(Chairman of the Mother & Child Substudy), F
Scho¨ni-Affolter, P Schmid, J Schu¨pbach, R Speck,
P Tarr, A Telenti, A Trkola, P Vernazza, R Weber,
S Yerly. Ethics committee approval: This analysis was
conducted in accordance with the Declaration of
Helsinki and approved by national ethical committee
where necessary.
Conflicts of interest
C.I.H., L.R., J.D.L., W.E.-S., F.D., S.D.W. and E.F. have
no conflicts of interest. C.Smith has received sponsorship
for the preparation of educational materials from Gilead
Sciences, Bristol Myers Squibb and ViiV Pharmeceu-
ticals. C.Smith has also attended an advisory board for
Gilead Sciences. R.W. has received travel grants from
Abbott, Boehringer Ingelheim, Bristol-Myers Squibb,
Gilead Sciences, GlaxoSmithKline, Merck Sharp &
Dome, Pfizer, Roche, TRB Chemedica and Tibotec.
R.W.’s institution has received unrestricted educational
grants from GlaxoSmithKline, ViiV, and Gilead Sciences.
P.R. has through his institution received independent
scientific grant support from Gilead Sciences, Janssen
Pharmaceuticals Inc, Merck & Co, Bristol-Myers Squibb
and ViiV Healthcare; he served on scientific advisory
board for Gilead Sciences; he serves on data safety
1594 AIDS 2016, Vol 30 No 10
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
monitoring committee for Janssen Pharmaceuticals Inc;
chaired a scientific symposium by ViiV Healthcare, for
which his institution has received remuneration. M.L. has
received unrestricted research grants from Boehringer
Ingelheim, Gilead Sciences, Merck Sharp & Dohme,
Bristol-Myers Squibb, Janssen-Cilag, and ViiV Health-
Care, and DSMB siting fees from Sirtex Pty Ltd.
A.D.A.M. has received grants for Advisory boards by
Abbvie, BMS, Janssen, Gilead, MSD, ViiV Italy.
A.d’A.M.’s institution has received grants for research
from Gilead, Janssen, ViiV. A.M. has received honoraria,
lecture fees or travel grants from Merck, BMS, Gilead,
BI, Pfizer and Wragge LLC. A.P. has been speaking
at national meetings sponsored by Gilead, attended
Abbvie Advisory Board and Consultancy with GSK
Biologicals. All of these are in the past 3 years but none
are ongoing. C.Sabin has received funding for member-
ship of Data Safety and Monitoring Boards, Advisory
Boards, for the preparation of educational materials and
for membership of speaker bureaux from Gilead
Sciences, ViiV Healthcare, Janssen-Cilag and Bristol-
Myers Squibb.
This project was presented at CROI 3–6 of March 2013,
Atlanta, GA, USA.
References
1. Nguyen HL, Saczynski JS, Gore JM, Waring ME, Lessar D,
Yarzebski J, et al. Long-term trends in short-term outcomes
in acute myocardial infarction. Am J Med 2011; 124:939–946.
2. Ford ES, Ajani UA, Croft JB, Crithchley JA, Labarte DR, Kottke
TE, et al. Explaining the decrease in U.S. deaths from coronary
disease, 1980-2000. N Engl J Med 2007; 356:2388–2398.
3. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly
W, et al. Metabolic syndrome in HIV-infected patients from an
urban, midwestern US outpatient population. Clin Infect Dis
2007; 44:726–734.
4. Perello´ R, Calvo M, Miro´ O, Castan˜eda M, Saubı´ N, Camo´n S,
et al. Clinical presentation of acute coronary syndrome in HIV
infected adults: a retrospective analysis of a prospectively
collected cohort. Eur J Intern Med 2011; 22:485–488.
5. Glass TR, Ungsedhapand C,Wolbers M,Weber R, Vernazza PL,
Rickenbach M, et al. Prevalence of risk factors for cardiovas-
cular disease in HIV-infected patients over time: the Swiss HIV
Cohort Study. HIV Med 2006; 7:404–410.
6. Sabin C, d’ArminioMonforte A, Friis-Moller N,Weber R, El-Sadr
WM, Reiss P, et al. Changes over time in risk factors for
cardiovascular disease and use of lipid-lowering drugs in
HIV-infected individuals and impact on myocardial infarction.
Clin Infect Dis 2008; 46:1101–1110.
7. Friis-Moller N, Sabin C,Weber R, d’ArminioMonforte A, El-Sadr
WM, Reiss P, et al. Adverse Events of Anti-HIV Drugs (DAD)
Study Group. Combination antiretroviral therapy and the risk
of myocardial infarction. N Engl J Med 2003; 349:1993–2003.
8. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR,
Sørensen HT, et al. Ischemic heart disease in HIV-infected and
HIV-uninfected individuals: a population-based cohort study.
Clin Infect Dis 2007; 44:1625–1631.
9. Lang S, Mary-KrauseM, Cotte L, Gilquin J, PartisaniM, Simon A,
et al. for the French Hospital database on HIV-ANRS CO4.
Impact of individual antiretroviral drugs on the risk of myo-
cardial infarction in human immunodeficiency virus-infected
patients: a case-control study nested within the French Hospi-
tal Database on HIV ANRS cohort CO4. Arch Intern Med 2010;
170:1228–1238.
10. Friis-Møller N, Reiss P, Sabin C, Weber R, d’Arminio Monforte
A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of
myocardial infarction. N Engl J Med 2007; 356:1723–1735.
11. Sabin C, Worm SW,Weber R, Reiss P, El-Sadr W, Dabis F, et al.
Use of nucleoside reverse transcriptase inhibitors and risk of
myocardial infarction in HIV-infected patients enrolled in the
D: A: D study: a multicohort collaboration. Lancet 2008;
371:1417–1426.
12. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al.
Risk of myocardial infarction in patients with HIV infection
exposed to specific individual antiretroviral drugs from the 3
major drug classes: the data collection on adverse events of
anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318–330.
13. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute
myocardial infarction rates and cardiovascular risk factors
among patients with human immunodeficiency virus disease.
J Clin Endocrinol Metab 2007; 92:2506–2512.
14. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D.
Increased risk of myocardial infarction with duration of pro-
tease inhibitor therapy in HIV-infected men. AIDS 2003;
17:2479–2486.
15. Save`s M, Cheˆne G, Ducimetie`re P, Leport C, le Moal G,
Amouyel P, et al. Risk factors for coronary heart disease in
patients treated for human immunodeficiency virus infection
compared with the general population. Clin Infect Dis 2003;
37:292–298.
16. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M,
et al. Increased carotid intima-media thickness in HIV patients
is associated with increased cytomegalovirus-specific T-cell
responses. AIDS 2006; 20:2275–2283.
17. Lang S, Mary-KrauseM, Cotte L, Gilquin J, PartisaniM, SimonA,
et al. Increased risk of myocardial infarction in HIV-infected
patients in France, relative to the general population. AIDS
2010; 24:1221–1230.
18. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K,
et al. Acute coronary syndrome in human immunodeficiency
virus-infected patients: characteristics and 1 year prognosis.
Eur Heart J 2011; 32:41–50.
19. Klein DB, Leyden WA, Xu L, Chao CR, Horberg MA, Towner
WJ, et al. Declining relative risk for myocardial infarction
among HIV-positive compared with HIV-negative individuals
with access to care. Clin Infect Dis 2015; 60:1278–1280.
20. Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C,
Gerstoft J, Obel N. Time trends for risk of severe age-related
diseases in individuals with and without HIV infection in
Denmark: a nationwide population-based cohort study. Lancet
HIV 2015; 2:e288–e298doi: 10.1016/S2352-3018 (15)00077-6.
21. Pocock S, Bueno H, Licour M, Medina J, Zhang L, Annemans L,
et al. Predictors of one-year mortality at hospital discharge
after acute coronary syndromes: a new risk score from the
EPICOR (long-term follow up of antithrombotic management
patterns in acute coronary syndrome patients) study. Eur Hear J
Acute Cardiovasc Care 2015; 4:509–517.
22. D’Ascenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omede` P,
Sciuto F, et al. Acute coronary syndromes in human immuno-
deficiency virus patients: a meta-analysis investigating adverse
event rates and the role of antiretroviral therapy. Eur Heart J
2012; 33:875–880.
23. Carballo D, Delhumeau C, Carballo S, Ba¨hler C, Radovanovic
D, Hirschel B, et al. Increased mortality after a first myocardial
infarction in human immunodeficiency virus-infected patients;
a nested cohort study. AIDS Res Ther 2015; 12:1–9.
24. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Raja-
kangas AM, Pajak A. Myocardial infarction and coronary
deaths in the World Health Organization MONICA Project.
Registration procedures, event rates, and case-fatality rates in
38 populations from 21 countries in four continents. Circula-
tion 1994; 90:583–612.
25. Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A,
Sabin C, et al. The Coding Causes of Death in HIV (CoDe)
Project: initial results and evaluation of methodology. Epide-
miology 2011; 22:516–523.
26. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. Executive summary of the third
report of the National Cholesterol Education Program (NCEP)
Expert Panel on De- tection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001; 285:2486–2497.
Short-term mortality after myocardial infarction Hatleberg et al. 1595
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
27. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS.
Population trends in the incidence and outcomes of acute
myocardial infarction. N Engl J Med 2010; 362:2155–2165.
28. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill
A, et al. Clinical features of acute coronary syndromes in
patients with human immunodeficiency virus infection. Circu-
lation 2004; 109:316–319.
29. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P,
Sacchi P, et al. Hypertension among HIV patients: prevalence
and relationships to insulin resistance and metabolic syn-
drome. J Hypertens 2003; 21:1377–1382.
30. Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an
urban HIV-positive population compared with the general
population: influence of combination antiretroviral therapy.
J Hypertens 2008; 26:2126–2133.
31. Calvo-Sa´nchez M, Perello´ R, Pe´rez I, Mateo M, Junyent M,
Laguno M, et al. Differences between HIV-infected and unin-
fected adults in the contributions of smoking, diabetes and
hypertension to acute coronary syndrome: two parallel case-
control studies. HIV Med 2013; 14:40–48.
32. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al.
Trends in underlying causes of death in people with HIV from
1999 to 2011 (D:A:D): a multicohort collaboration. Lancet
2014; 384:241–248.
33. Antiretroviral therapy Cohort Collaboration. Causes of death in
HIV-1-infected patients treated with antiretroviral therapy,
1996–2006: Collaborative Analysis of 13 HIV Cohort Studies.
Clin Infect Dis 2010; 50:1387–1396.
34. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola
D, et al. Changes in causes of death among adults infected by
HIV between 2000 and 2005: the ‘‘Mortalite´ 2000 and 2005’’
Surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic
Syndr 2008; 48:590–598.
35. Ambrose JA, Gould RB, Kurian DC, DeVoe MC, Pearlstein NB,
Coppola JT, et al. Frequency of and outcome of acute
coronary syndromes in patients with human immuno-
deficiency virus infection. Am J Cardiol 2003; 92:301–
303.
36. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al.
Acute myocardial infarction in human immunodeficiency
virus-infected patients. Arch Intern Med 2003; 163:457–
460.
37. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial
infarction in patients infected with human immunodeficiency
virus. Am Heart J 2004; 147:55–59.
38. Chaudhry SI, Khan RF, Chen J, Dharmarajan K, Dodson JA,
Masoudi FA, et al. National trends in recurrent ami hos-
pitalizations 1 year after acute myocardial infarction in
medicare beneficiaries: 1999-2010. J Am Heart Assoc 2014;
3:e001197.
39. Rosengren A,Wallentin L, Gitt AK, Behar S, Battler A, Hasdai D.
Sex, age, and clinical presentation of acute coronary syn-
dromes. Eur Heart J 2004; 25:663–670.
40. Lorgis L, Cottenet J, Molins G, Benzenine E, Zeller M, Aube H,
et al. Outcomes after acute myocardial infarction in HIV-
infected patients: analysis of data from a french nationwide
hospital medical information database. Circulation 2013;
127:1767–1774.
41. Grunfeld C. Dyslipidemia and its treatment in HIV infection.
Top HIV Med 2010; 18:112–118.
42. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD,
French WJ, et al., For the NRMI Investigators. Number
of coronary heart disease risk factors and mortality in patients
with first myocardial infarction. JAMA 2011; 306:2120–
2127.
1596 AIDS 2016, Vol 30 No 10
